Patient views on receiving a pharmacogenetic passport - a mixed methods study exploring experiences and use after an opportunistic offer.

Genomic data plays an increasingly important role in clinical care, yet how it can be appropriately integrated into standard practice remains debated. One emerging approach is the opportunistic use of whole-exome sequencing (WES) data to offer pharmacogenetic (PGx) information. While initiatives providing PGx prescribing recommendations ahead of actual prescriptions are growing, little is known about how recipients of such information use it in practice or how it shapes their perceived roles and responsibilities. Using a mixed-methods design combining a quantitative survey with qualitative interviews, we explored the experiences and use of an opportunistic PGx passport, that was offered to parents who had undergone a trio-WES in pursuit of a genetic diagnosis for their child's developmental delay. We examined how they experienced and used the passport in practice and how it influenced their perceived role and responsibilities in a care setting. A total of 44 respondents were included in this study. The passport was used by only a minority of participants, partly due to the absence of a current medication need, but primarily due to limited ability to understand and apply the PGx information. The PGx passport shifted responsibilities away from the digital healthcare information systems onto the individual recipient. Without adequate support, this shift risks responsibilizing recipients rather than genuinely empowering them with access to their PGx profiles. Based on these findings, we offer recommendations for the implementation of similar opportunistic PGx offers and for policy focussing on the appropriate integration of PGx into standard healthcare practice.